论文信息 - KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). - 字舞流文

KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

R. Greil | K. Harrington | A. Psyrri | D. Rischin | R. Swaby | B. Burtness | N. Ngamphaiboon | B. Hughes | R. Mesía | A. Bratland | D. Soulières | T. Fuereder | M. Tahara | P. Neupane | T. Rordorf | G. Castro | N. Basté | W. Z. W. Ishak | Yayan Zhang | B. Gumuscu